Comment on: ‘Clinical and Economic Impact of a Potential Switch from 13-Valent to 10-Valent Pneumococcal Conjugate Infant Vaccination in Canada’, Wilson et al., 22 June 2018 by Ashleigh McGirr, Shehzad M. Iqbal, Jan Olbrecht, Lijoy Varghese

Get full text

How to assess for the full economic value of vaccines? From past to present, drawing lessons for the future by Baudouin Standaert, Christophe Sauboin, Rodrigo DeAntonio, Alen Marijam, Jorge Gomez, Lijoy Varghese, Sharon Zhang

Get full text

Health economic assessment of a rabies pre-exposure prophylaxis program compared with post-exposure prophylaxis alone in high-risk age groups in the Philippines by Beatriz Quiambao, Lijoy Varghese, Nadia Demarteau, Ruth Faye Sengson, Jenaline Javier, Piyali Mukherjee, Leah Cheryl Manio, Scott Preiss

Get full text

Assessment of the potential public health impact of Herpes Zoster vaccination in Germany by Desmond Curran, Desirée Van Oorschot, Lijoy Varghese, Lidia Oostvogels, Tomas Mrkvan, Romulo Colindres, Alfred von Krempelhuber, Anastassia Anastassopoulou

Get full text

Cost-effectiveness of the recombinant zoster vaccine in the German population aged ≥60 years old by Desirée Van Oorschot, Anastassia Anastassopoulou, Barbara Poulsen Nautrup, Lijoy Varghese, Alfred von Krempelhuber, Mohamed Neine, Stéphane Lorenc, Desmond Curran

Get full text